BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that it has successfully produced a further two full-scale fillets of cultivated pork, as well as a cultivated pork strip, which were presented at a technical event on Friday 25 May 2023.
The cultivated pork fillets each measured 5 cm in diameter, 3 cm in height, and circa 60 g in weight, making them similar in size to traditional 2-ounce tenderloin steaks. This time, the Company had worked on increasing the thickness of the fillet in comparison to the fillet produced in January this year. In addition, the Company produced a cultivated pork strip, or 'noodle' measuring circa 30 cm in length and 1 cm in diameter. The development of the pork strip demonstrates the effectiveness of the Company's intellectual property in being applied to produce meat in the future as a consumer-ready, 'pre-sliced' form for cooking purposes.
The cultivated meat products were produced using 3DBT's patented, serum-free and animal-free cell booster City-MixTM, which eliminates the requirement of conventional plant-based scaffolds, blends or fillers, as have been universally adopted by the industry to date to ensure structural integrity of cultivated meat products. 3DBT's products are therefore 100% structured meat, produced without any animals suffering in its production.
The latest iteration of 100% meat products underwent testing, with data collected and study participants invited to inspect the product in a raw and cooked state. Study participants were limited to those persons who had a direct working relationship or involvement with the Company. The cultivated meat fillets were then pan-fried and presented formally by a trained, independent chef, while the meat strip was first cut in two portions, and subsequently poached or pan-fried, in order to test an array of cooking methods. The chef's involvement was key to demonstrating that the cultivated meat could be handled and cooked in the same way as traditional meat, and the results were very positive.
The Company is pleased to confirm that the 100% cultivated meat products were very similar in appearance to conventional meat in their raw state, with fibres clearly visible. The results from cutting and cooking the fillets were also consistent with the previous results in terms of overall appearance, aroma and searing/crisping. The Study participants that tasted the cultivated meat provided very positive feedback in terms of its taste and texture.
Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues, commented:"We have gained a huge amount of valuable knowledge from testing our products with a trained chef and we were reassured to observe that our cultivated meat is able to be handled and cooked in the same way as traditional meat products. Further, data collected from the study participants indicated comparable meat qualities to traditional pork meat, which was very pleasing and highly validating of our work. This gives us further confidence as we continue our conversations with potential customers to licence out the technologies demonstrated as well as building on the agreements already secured."
Photographs of the cultivated meat products in raw and cooked states from the Test Event can be found below:
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory using its technology.
BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.
Stay connected and informed.
Get the latest company news, scientific developments, product launches, and more direct to your inbox with our free weekly newsletter.
Thank you! You will hear from us soon!
Oops! Something went wrong while submitting the form.
Cell Based News Showcasing the scientific breakthroughs, exciting companies and industry pioneers leading the cell based food and materials revolution. Contact: email@example.com